Fluicell
34.50 SEK
+12.38 %
Less than 1K followers
FLUI
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+12.38 %
+161.36 %
+213.64 %
+245.00 %
+202.63 %
+200.00 %
-80.51 %
-97.95 %
-96.88 %
Fluicell operates in biotechnology. The company conducts research and development in the processing of cell composition in the development of new drugs. The company has developed a product portfolio consisting of patented research instruments, which are used to study, analyze and ultimately process cells. In addition, there is expertise in 2D/3D printing. Fluicell was founded in 2012 and is headquartered in Gothenburg.
Read moreMarket cap
47.39M SEK
Turnover
988.37K SEK
Revenue
6M
EBIT %
-139.87 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
3/6
2026
General meeting '26
14/8
2026
Interim report Q2'26
13/11
2026
Interim report Q3'26
All
Press releases
3rd party
ShowingAll content types
Karin Jennbacken föreslås som ny styrelseledamot i Fluicell AB
Valberedningen i Fluicell AB föreslår ny styrelse med avsikt att möte framtida behov av kommersiell utveckling och regulatorisk expertis
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools